Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 19:48:44·⟳ 抓取 19:49:12 +28s·⚡ 决策 10-08 19:52:07 +2m55s·19.2 天前
Viatris将以16.5亿美元现金收购Pacira BioSciences
PCRX的主要溢价将在开盘集中反映，未成交前无法确认仍有足够套利价差；VTRS虽称交易即时增厚，但盘前反应偏负面且增量相对市值有限，多空均缺乏明确正期望。
📄 原文Investing.com↗ 原文
Viatris to acquire Pacira BioSciences for $1.65 billion
By Investing.com Advertisement Advertisement Viatris to acquire Pacira BioSciences for $1.65 billion Company News Publi…
不做 Pacira BioSciences, Inc.（PCRX.US）
每股36.50美元的现金对价已明确，主要溢价可能在正式开盘一次性反映；盘前报价低流动性且买卖盘异常，无法确认开盘后仍存在补偿监管与交易失败风险的足够价差。
不做 Viatris Inc.（VTRS.US）
交易虽预计即时增厚，但新增资产相对Viatris市值有限且盘前股价下跌约1.66%，没有明确正预期差；该跌幅也不构成可主动做空的强利空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Viatris以16.5亿美元收购Pacira并获得EXPAREL、ZILRETTA，标的公司获得显著现金溢价，但当前处于美股盘前且报价不充分；开盘后标的股大概率接近要约价，买方股价则初步走弱，因此风险回报不支持即时交易。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 medium ↗
消息传播链
- Investing.com称其依据公司新闻稿报道最终协议，内容列明每股36.50美元、16.5亿美元股权价值及EXPAREL、ZILRETTA两项资产，但该文由AI辅助生成且未直接链接公司原始通稿。市场反应:VTRS盘前约17.20美元、下跌1.66%；PCRX盘前报价约25.72美元但成交极少且买卖盘异常交叉。
关键理由
- PCRX收购溢价高但属于已签约现金要约，开盘后主要收益可能已被重定价，剩余价差主要是并购套利风险补偿。
- VTRS获得约7.46亿美元年收入资产并称即时增厚，但16.5亿美元交易相对其约200.9亿美元市值不大，盘前走势不支持追多。
主要风险
- 若监管审查、融资或股东要约出现障碍，PCRX可能回落至25美元附近的交易前区间。
- 若正式开盘后PCRX仍显著低于36.50美元且VTRS获得卖方积极评价，当前不做结论可能错过套利或买方重估机会。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
当前报道列示多数股份要约和监管等待期为交割条件，且交易由超额现金及短期借款融资；这些条件削弱PCRX开盘追涨的风险回报。
检索:Viatris Pacira acquisition risk antitrust financing deal failure official press release 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
Viatris称交易预计即时增厚公司财务指引指标且对总杠杆率影响很小，未出现足以支撑做空的强基本面损害。
检索:Viatris Pacira immediately accretive EXPAREL ZILRETTA cash leverage guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不做趋势性追多，也不据弱负面盘前反应做空VTRS；结论主要基于合同价差、相对市值和开盘重定价风险。
方向:检索到多起2025至2026年医药并购案例，但公开结果多为聚合媒体或管线型并购，缺少与本次成熟药品现金要约、交易规模和当前盘前相位均对齐且可确认首发时刻的样本。
涨幅量级:未使用任何先例校准PCRX或VTRS的目标涨幅；PCRX的短期锚点直接采用合同对价36.50美元，VTRS则以实时盘前反应作为主要依据。
形态:未形成足以判断本次会反复见光死或高开低走的高相似样本。
工具执行结果 · 成功 9 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 17 ms
{"result": "search_processed_events:agent query=`viatris acquire pacira biosciences $36.50 per share $1.65 billion | vtrs pcrx tender offer exparel zilretta definitive agreement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 492 ms
{ - stock_quote 成功 stock_tools HTTP · 896 ms
{ - web_search 成功 doubao_search · 2,092 ms
豆包搜索结果（原始查询:Viatris Pacira acquisition $36.50 premium EXPAREL ZILRETTA investor reaction；API SearchType:web） - fetch_decision_experience 成功 stock_tools HTTP · 10 ms
{ - web_search 成功 doubao_search · 694 ms
web_search「site:investor.viatris.com Pacira BioSciences definitive agreement $36.50 October 8 2026」无结果。 - web_search 成功 doubao_search · 1,789 ms
豆包搜索结果（原始查询:Reuters October 8 2026 Viatris Pacira BioSciences acquisition；API SearchType:web） - web_search 成功 doubao_search · 1,436 ms
豆包搜索结果（原始查询:pharmaceutical company cash acquisition announced acquirer shares fell immediately accretive deal examples 2024 2025；API SearchType:web） - web_search 成功 doubao_search · 6,447 ms
豆包搜索结果（原始查询:site:prnewswire.com OR site:businesswire.com pharmaceutical company announces definitive acquisition cash all outstanding shares immediately accretive 2025 pharma；API SearchType:web）
原文全文
展开原文 · 7,887 字
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com
Advertisement
Advertisement
Viatris to acquire Pacira BioSciences for $1.65 billion
Company News
Published
Oct 08, 2026, 07:48 AM
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
© Reuters
In this article:
VTRS
-0.29%
PCRX
+
1.78%
PITTSBURGH and BRISBANE, Calif. -
Viatris
Inc. (
NASDAQ:VTRS
) announced today it has entered into a definitive agreement to acquire
Pacira
BioSciences, Inc. (
NASDAQ:PCRX
) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, according to a press release statement.
Under the terms of the transaction, Viatris will commence a tender offer to acquire all outstanding shares of Pacira’s common stock. Following completion of the tender offer, Viatris will acquire remaining shares through a second-step merger for the same consideration.
The acquisition adds two patent-protected products to Viatris’ portfolio: EXPAREL, a bupivacaine liposome injectable suspension for acute postsurgical pain, and ZILRETTA, a triamcinolone acetonide extended-release injectable suspension for osteoarthritis knee pain. Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA during the twelve months ended June 30, 2026.
"The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business," said Scott A. Smith, CEO of Viatris.
Paul Campbell, Interim CFO of Viatris, stated the transaction is expected to be immediately accretive to the company’s financial guidance metrics. Viatris expects to fund the transaction primarily from excess cash with the remainder from short-term borrowings, with minimal impact on its gross leverage ratio.
The transaction, unanimously approved by both companies’ boards of directors, is subject to customary closing conditions, including the tender of a majority of Pacira’s outstanding shares and expiration of the applicable regulatory waiting period. Pacira’s board unanimously recommends that stockholders tender their shares in the offer.
The transaction is expected to close by the end of 2026. Upon completion, Pacira will become a wholly owned subsidiary of Viatris and Pacira’s common stock will no longer be listed on the Nasdaq Global Select Market.
Morgan Stanley & Co. LLC is serving as financial advisor to Viatris, with Cravath, Swaine & Moore LLP as legal advisor. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Pacira, with Ashurst Perkins Coie as legal advisor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,754.10
-425.1
-0.83%
US 500
7,764.90
-36.8
-0.47%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.79
+0.71
+4.71%
Dollar Index
102.21
+0.197
+0.19%
Crude Oil WTI Futures
92.33
+4.05
+4.59%
Brent Oil Futures
104.72
+4.52
+4.51%
Natural Gas Futures
3.253
+0.050
+1.56%
Gold Futures
4,147.47
+6.77
+0.16%
Silver Futures
59.035
-1.259
-2.09%
Copper Futures
6.6308
-0.0187
-0.28%
US Soybeans Futures
1,293.75
-3.25
-0.25%
U.S. 10Y
5.333
+0.055
+1.04%
U.S. 30Y
5.705
+0.044
+0.78%
U.S. 5Y
5.077
+0.056
+1.12%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.08
-0.41
-0.39%
Euro Bund Futures
120.62
-0.20
-0.16%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Viatris to acquire Pacira BioSciences for $1.65 billion
Company News
Published
Oct 08, 2026, 07:48 AM
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
© Reuters
In this article:
VTRS
-0.29%
PCRX
+
1.78%
PITTSBURGH and BRISBANE, Calif. -
Viatris
Inc. (
NASDAQ:VTRS
) announced today it has entered into a definitive agreement to acquire
Pacira
BioSciences, Inc. (
NASDAQ:PCRX
) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, according to a press release statement.
Under the terms of the transaction, Viatris will commence a tender offer to acquire all outstanding shares of Pacira’s common stock. Following completion of the tender offer, Viatris will acquire remaining shares through a second-step merger for the same consideration.
The acquisition adds two patent-protected products to Viatris’ portfolio: EXPAREL, a bupivacaine liposome injectable suspension for acute postsurgical pain, and ZILRETTA, a triamcinolone acetonide extended-release injectable suspension for osteoarthritis knee pain. Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA during the twelve months ended June 30, 2026.
"The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business," said Scott A. Smith, CEO of Viatris.
Paul Campbell, Interim CFO of Viatris, stated the transaction is expected to be immediately accretive to the company’s financial guidance metrics. Viatris expects to fund the transaction primarily from excess cash with the remainder from short-term borrowings, with minimal impact on its gross leverage ratio.
The transaction, unanimously approved by both companies’ boards of directors, is subject to customary closing conditions, including the tender of a majority of Pacira’s outstanding shares and expiration of the applicable regulatory waiting period. Pacira’s board unanimously recommends that stockholders tender their shares in the offer.
The transaction is expected to close by the end of 2026. Upon completion, Pacira will become a wholly owned subsidiary of Viatris and Pacira’s common stock will no longer be listed on the Nasdaq Global Select Market.
Morgan Stanley & Co. LLC is serving as financial advisor to Viatris, with Cravath, Swaine & Moore LLP as legal advisor. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Pacira, with Ashurst Perkins Coie as legal advisor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Viatris to acquire Pacira BioSciences for $1.65 billion
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,754.10
-425.1
-0.83%
US 500
7,764.90
-36.8
-0.47%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.79
+0.71
+4.71%
Dollar Index
102.21
+0.197
+0.19%
Crude Oil WTI Futures
92.33
+4.05
+4.59%
Brent Oil Futures
104.72
+4.52
+4.51%
Natural Gas Futures
3.253
+0.050
+1.56%
Gold Futures
4,147.47
+6.77
+0.16%
Silver Futures
59.035
-1.259
-2.09%
Copper Futures
6.6308
-0.0187
-0.28%
US Soybeans Futures
1,293.75
-3.25
-0.25%
U.S. 10Y
5.333
+0.055
+1.04%
U.S. 30Y
5.705
+0.044
+0.78%
U.S. 5Y
5.077
+0.056
+1.12%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.08
-0.41
-0.39%
Euro Bund Futures
120.62
-0.20
-0.16%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。